Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders for ImmuCell Corporation, held remotely on June 13, 2024. The meeting addressed director elections, executive compensation, and the ratification of the independent auditor.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
A total of 6,071,108 shares were present, representing over 78% of eligible votes. The following proposals were approved:
- Director Elections: All seven nominees were elected to one-year terms. While all were approved, significant broker non-votes (1,649,057) were recorded for each nominee.
- Executive Compensation: The non-binding advisory resolution was approved with 66% of votes cast in favor (4,013,133 For vs. 114,706 Against).
- Auditor Ratification: The selection of Wipfli LLP as the independent registered public accounting firm for the year ending December 31, 2024, was ratified with 99.5% of votes cast in favor (6,041,186 For vs. 10,089 Against).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a disclosure of voting outcomes.
Investor Verification Checklist
- Verify the specific vote counts for each director nominee, noting the high volume of broker non-votes.
- Confirm the approval of Wipfli LLP as the auditor for the fiscal year ending December 31, 2024.
- Review the 2024 Proxy Statement (dated April 26, 2024) referenced in the filing for detailed biographical information on the elected directors and executive compensation details.
- Consult the company's most recent 10-K or 10-Q filings for actual financial performance metrics, as this 8-K does not include them.